

## Editorial

# A new era for GPCR research: structures, biology and drug discovery

H Eric XU<sup>1,2,\*</sup>, Rui-ping XIAO<sup>3,4,\*</sup>

<sup>1</sup>VARI-SIMM Center, Center for Structure and Function of Drug Targets, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; <sup>2</sup>Laboratory of Structural Sciences, Van Andel Research Institute, 333 Bostwick Ave, NE, Grand Rapids, MI 49503, USA; <sup>3</sup>Institute of Molecular Medicine, Center for Life Sciences, Peking University, Beijing 100871, China; <sup>4</sup>Drug Discovery Center, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen 518055, China

Acta Pharmacologica Sinica (2012) 33: 289–290; doi: 10.1038/aps.2012.16

Cells in a living organism must communicate with each other through continuously sending and receiving messages. G-protein coupled receptors (GPCRs) are the largest family of communicating molecules at the cell surface. They transmit diverse extracellular signals, ranging from light and small chemical hormones to large peptide and protein hormones, and as such they play crucial roles in numerous physiological and pathological processes. More importantly, GPCRs are the most successful class of drug targets that are relevant to many major diseases, including cancer, heart failure, and inflammatory diseases. Over 50% of currently used drugs are targeted to GPCRs. However, these drugs target only 50–60 GPCRs, leaving the majority of human GPCRs, exceeding 800, unexplored for drug discovery. Given the prominent roles of GPCRs in biology and their successful track records as drug targets, GPCRs have become a hot frontier in basic research of life science and therapeutic discovery of translational medicines.

In this special issue, there are nine exciting reviews that cover a broad scope of GPCR structures, biology, diseases, and drug discovery. Among them, four reviews are dedicated to GPCR structures. Over the last few years, we have witnessed a revolution in Class A GPCR structural biology. Rhodopsin is the founding member of the GPCR family and its signaling mechanism is a paradigm for many other GPCRs. The crystal structure of bovine rhodopsin was first solved in 2000 and since then structures of rhodopsin have been solved in several functional states, including the inactivated dark state, partially

active opsin, and the fully active state that is bound with a G<sub>at</sub> peptide. ZHOU, MELCHER, and XU review the signaling mechanisms gained from rhodopsin structures and compare these mechanisms to other members of Class A GPCRs, most notably  $\beta$ 2-adrenergic receptor ( $\beta$ 2AR)<sup>[1]</sup>. Class B and C GPCRs distinguished themselves from Class A GPCRs by having a large extracellular domain for binding of ligands. Compared to Class A GPCRs, structure determination for the full-length receptors of other families of GPCRs is lagging behind. However, structures for a half dozen of Class B and C GPCR extracellular domains (ECDs) in complex with their respective ligands have been determined. The structures and ligand binding mechanisms of Class B and Class C GPCRs will be reviewed by the XU and LIU groups, respectively<sup>[2,3]</sup>. The rapid explosion of Class A GPCR structures is owed to technology development in various stages of structure determination; including protein expression, purification, crystallization, and X-ray diffraction, for which a thorough review is provided by ZHAO and WU<sup>[4]</sup>.

Following the reviews of GPCR structures, five reviews are focused on GPCR biology, diseases, and drug discovery.  $\beta$ 2AR is a prototype of GPCRs, and in parallel to rhodopsin, it has been serving as a model for studying other GPCRs. WOO and XIAO review the signaling mechanisms by  $\beta$ -adrenergic receptor subtypes that provide a basis for developing selective biased  $\beta$ 2 agonists for the treatment of heart failure<sup>[5]</sup>. Moving from heart to immune systems, YE and SUN review the role of GPCRs in inflammation processes from chemotaxis to transcriptional regulation of inflammation programs<sup>[6]</sup>. Lappano and Maggolini provide a systematic review on the relationship of cancers with various subfamilies of GPCRs, which may serve as the basis for developing novel pharmacological interventions for cancers<sup>[7]</sup>. A large number of GPCRs are orphan

\* To whom correspondence should be addressed.

E-mail eric.xu@vai.org (H Eric XU);

xiaor@pku.edu.cn (Rui-ping XIAO)

Received 2012-01-27 Accepted 2012-02-06

receptors whose ligand remains unknown. Despite missing cognate ligands, many orphan GPCRs are known to play important physiological functions, mostly from genetic knock-out studies. LIU and colleagues provide a thorough review on different class of orphan nuclear receptors, their functions, and possible strategies for identification of endogenous ligands<sup>[8]</sup>. Finally, as one of the most important drug targets, GPCRs are widely pursued by both academic and industrial research for drug discovery. ZHANG and XIE provide a comprehensive review on methods of GPCR drug discovery, including various ligand binding and cell-based functional assays, many of which are tool kits for basic research as well as drug discovery for GPCRs<sup>[9]</sup>.

Followed the waves of technological advances and interdisciplinary approaches in modern biological research, the field of GPCRs is evolving rapidly into a new phase of exciting progresses. With a rich history of biology and drug discovery, GPCR research is expected to continue to be a dominant source of innovative medicines for the 21st Century. We hope that the collection of these nine exciting reviews will provide a window into this new era of GPCR research and drug discovery.

## References

- 1 Zhou XE, Melcher K, Xu HE. Structure and activation of rhodopsin. *Acta Pharmacol Sin* 2012; 33: 291–9.
- 2 Pal K, Melcher K, Xu HE. Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors. *Acta Pharmacol Sin* 2012; 33: 300–11.
- 3 Chun L, Zhang WH, Liu JF. Structure and ligand recognition of Class C GPCRs. *Acta Pharmacol Sin* 2012; 33: 312–23.
- 4 Zhao Q, Wu BL. Ice breaking in GPCR structural biology. *Acta Pharmacol Sin* 2012; 33: 324–34.
- 5 Woo AY, Xiao RP.  $\beta$ -Adrenergic receptor subtype signaling in heart: From bench to bedside. *Acta Pharmacol Sin* 2012; 33: 335–41.
- 6 Sun L, Ye RD. Role of G protein-coupled receptors in inflammation. *Acta Pharmacol Sin* 2012; 33: 342–50.
- 7 Lappano R, Maggiolini M. GPCRs and cancer. *Acta Pharmacol Sin* 2012; 33: 351–62.
- 8 Tang XL, Wang Y, Li DL, Luo J, Liu MY. Orphan G protein-coupled receptors (GPCRs): biological functions and potential drug targets. *Acta Pharmacol Sin* 2012; 33: 363–71.
- 9 Zhang R, Xie X. Tools for GPCR drug discovery. *Acta Pharmacol Sin* 2012; 33: 372–84.